Clinical studies with levodopa/carbidopa intestinal gel;Levodopa/carbi dopa intestinalis géllel végzett klinikai vizsgálatok

Ideggyogyaszati Szemle

Volumn 67, Issue 1-2, 2014, Pages 5-8

  Klivényi, Péter ^a   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Jejuna levodopa; Motor complication; Parkinsons' disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTICLE; CLINICAL STUDY; GEL; HUMAN; INFUSION PUMP; JEJUNUM; PARKINSON DISEASE; QUALITY OF LIFE; DRUG EFFICACY; INTESTINE; REVIEW; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); COGNITION; DRUG DELIVERY SYSTEM; DRUG EFFECT; EPIDEMIOLOGY; METHODOLOGY; PERIPHERAL NEUROPATHY; SAMPLE SIZE; SLEEP;

ANTIPARKINSON AGENTS; CARBIDOPA; CLINICAL TRIALS AS TOPIC; COGNITION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOPAMINE AGENTS; DRUG DELIVERY SYSTEMS; GELS; HUMANS; INTESTINES; LEVODOPA; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RESEARCH DESIGN; SAMPLE SIZE; SLEEP;

EID: 84898026421     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Poewe W, Antonini A, Zijlmans J.C., Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010;5:229-38.
2. Honig H, Antonini A, Martinez-Martin P, et al Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.
3. Martinez-Martin P., Rodriguez-Blazquez C, Kurds M.M., et al The impact of non motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
4. Reddy P, Martinez-Martin P, Rizos A., et al Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 2012;35:205-7.
5. Pàlhagen S.E., Dizdar N, Hauge T., et al Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 2012;126:29-33.
6. Nyholm, D, Remahl, N, Dizdar, N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23.
7. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012;19:1079-85.
8. Zibetti M, Merola A, Ricchi V., et al Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. J Neurol 2013;260:105-14.
9. Nyholm D, Lewander T, Johansson A., et al Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
10. Nilsson D, Nyholm D, Aquilonius SM Duodenal levodopa infusion in Parkinson's disease: long-term experience. Acta Neurol Scand 2001;104:343-8.
11. Eggert K, Schroder C, Hahn M., et al Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66.
12. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
13. Puente V, De Fabregues O, Oliveras C, et al Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21.
14. Kurth MC, Tetrud JW, Tanner C.M., et al Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off fluctuations. Neurology 1993;43:1698-703.
15. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Op 2011;27:907-19.
16. Zibetti M, Rizzone M, Merola A., et al Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand 2013;127:28-32.
17. Clarke CE, Worth P, Grosset D., et al Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinson Relat Disord 2009;15:728-41.
18. Johansson A, Nyholm D. Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa-carbidopa intestinal gel in the absence of head-to-head comparisons. Basal Ganglia 2009;2:221-6.
19. Abbruzzese G, Barone P, Bonuccelli U., Lopiano L, Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol 2012;27:147-54.